Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738945 | 0.90 | NPC1 (0.50) | NPC1MEN1KMT2AGAARAB9A | |
| SCHEMBL21765683 | 0.90 | NPC1 (0.50) | NPC1MEN1KMT2AGAARAB9A | |
| SCHEMBL3742024 | 0.82 | PTPN1 (0.54) | NPC1MEN1KMT2ARAB9APOLB | |
| SCHEMBL3737379 | 0.82 | PTPN1 (0.62) | NPC1MEN1KMT2AGAALMNA | |
| SCHEMBL3729171 | 0.79 | PTPN1 (0.54) | NPC1MEN1KMT2AGAARAB9A | |
| SCHEMBL15267699 | 0.78 | KMT2A (0.60) | NPC1MEN1KMT2AGAARAB9A | |
| SCHEMBL28755070 | 0.78 | HPGD (0.46) | NPC1MEN1KMT2ARAB9ALMNA | |
| SCHEMBL29375630 | 0.78 | L3MBTL1 (0.62) | MEN1KMT2AGAAPOLBLMNA | |
| SCHEMBL4787002 | 0.75 | KMT2A (0.51) | NPC1MEN1KMT2AGAARAB9A | |
| SCHEMBL8667875 | 0.75 | KMT2A (0.48) | MEN1KMT2AGAAPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278730-A1 | Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-11-04 | — | — | US | claimed |
| WO-2009009179-A2 | NON-INVASIVE MOLECULAR IMAGING OF CELLULAR HISTONE DEACETYLASE SUBSTRATE USING MAGNETIC RESONANCE SPECTROSCOPY (MRS) OR POSITRON EMISSION TOMOGRAPHY (PET) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-15 | — | — | WO | claimed |
| US-20100278730-A1 | Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-11-04 | — | — | US | disclosed |
| WO-2009009179-A2 | NON-INVASIVE MOLECULAR IMAGING OF CELLULAR HISTONE DEACETYLASE SUBSTRATE USING MAGNETIC RESONANCE SPECTROSCOPY (MRS) OR POSITRON EMISSION TOMOGRAPHY (PET) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278730-A1 | Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET) | HDAC1, HDAC3, HDAC10 | NPC1 1309/4885MEN1 612/4885KMT2A 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.